Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A

7(100.0%)

7Total

N/A(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04629807Not ApplicableUnknown

Anterior Gen Plus Study

Role: lead

NCT04364295Enrolling By Invitation

Stronger Together Global Registry

Role: lead

NCT04629794Not ApplicableUnknown

The OsteoStrand Plus Deformity Study

Role: lead

NCT04300777Unknown

The Fixation Study

Role: lead

NCT03871400Not ApplicableSuspended

The NanoStrand Clinical Study

Role: lead

NCT02018445Not ApplicableCompleted

Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion

Role: lead

NCT01873586Not ApplicableCompleted

OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion

Role: lead

NCT01430299Not ApplicableCompleted

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

Role: lead

NCT01714804Not ApplicableCompleted

Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion

Role: lead

All 9 trials loaded